References
- Alex MR, Chacko AJ, Jose S, Souto EB. 2011. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 42:11–18.
- Alvarez-Roman R, Naik A, Kalia YN, Guy RH, Fessi H. 2004. Skin penetration and distribution of polymeric nanoparticles. J Control Release. 99:53–62.
- Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. 2007. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 59:454–477.
- Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. 2010. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B Biointerfaces. 81:412–421.
- Jain NK, Ram A. 2011. Development and characterization of nanostructured lipid carriers of oral hypoglycemic agent: selection of surfactants. Int J Pharm Sci Rev Res. 7:125–130.
- Kumar VV, Chandrashekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV. 2007. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm. 335:167–175.
- Lin XH, Li XW, Zheng LQ, Yu L, Zhang QQ, Liu WC. 2007. Preparation and characterization of monocaprate nanostructured lipid carriers. Colloids Surf A. 311:106–111.
- Liu D, Liu Z, Wang L, Zhang C, Zhang N. 2011. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces. 85:262–269.
- Mehnert W, Mader K. 2001. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 47: 165–196.
- Muller RH, Keck CM. 2004. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 113:151–170.
- Muller RH, Radtke M, Wissing SA. 2002a. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 54: S131–S155.
- Muller RH, Radtke M, Wissing SA. 2002b. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 242:121–128.
- Parfitt K. 1999. The Complete Drug Reference. London: Pharmaceutical Press, p. 838.
- Potluri RK, Bandari S, Jukanti R, Veerareddy PR. 2011. Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with gelucire. Arch Pharm Res. 34: 51–57.
- Reddy LH, Vivek K, Bakshi N, Murthy RS. 2006. Tamoxifen citrate loaded solid lipid nanoparticles (SLN™): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm Dev Technol. 11:167–177.
- Schäfer-Korting M, Mehnert W, Korting HC. 2007. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 59:427–443.
- Singh S, Dobhal AK, Jain A, Pandit JK, Chakraborty S. 2010. Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: Zidovudine. Chem Pharm Bull. 58:650–655.
- Souto EB, Wissing SA, Barbosa CM, Muller RH. 2004. Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur J Pharm Biopharm. 58:83–90.
- Tiwari R, Pathak K. 2011. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm. 415:232–243.
- Triplett (II) MD, Rathman JF. 2009. Optimization of β-carotene loaded solid lipid nanoparticles preparation using a high shear homogenization technique. J Nanopart Res. 11:601–614.
- Trotta M, Debernardi F, Caputo O. 2003. Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique. Int J Pharm. 257:153–160.
- Venishettya VK, Chedea R, Komuravelli R, Adepua L, Sistla R, Diwan PV. 2012. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids Surf B Biointerfaces. 95:1–9.
- Venkateswarlu V, Manjunath K. 2004. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 95:627–638.